Author(s): Venkatesh MP, Placencia F, Weisman LE, Venkatesh MP, Placencia F, Weisman LE, Venkatesh MP, Placencia F, Weisman LE, Venkatesh MP, Placencia F, Weisman LE
Abstract Share this page
Abstract Coagulase-negative staphylococcus (CONS) infection is the most common bloodstream infection treated in neonatal and pediatric intensive care units and significantly impacts patient mortality and morbidity. Staphylococcus epidermidis is the most common CONS species isolated clinically and investigated for its pathogenicity and virulence. Difficulties exist in the differentiation of CONS infection from culture contamination in clinical specimens, as CONS is a common skin commensal. Most CONS isolates have the mecA gene and exhibit beta-lactam resistance. The glycopeptide antibiotics, such as vancomycin, are the mainstay in therapy, although resistance has been reported. Arbekacin, linezolid, and streptogramins are newer antibiotics being evaluated as alternatives to glycopeptides. Monoclonal and polyclonal antibodies have been developed against the cell-wall components of staphylococcus and may hold promise for immune prophylaxis and treatment of CONS infection.
This article was published in Semin Pediatr Infect Dis
and referenced in Journal of Data Mining in Genomics & Proteomics